Sandy Spring Bank’s Catalyst Pharmaceutical CPRX Stock Holding History

Sandy Spring Bank’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$49	Hold	2	–	–	﹤0.01%	1198
2024 Q4	$42	Buy	+2	New	+$43	﹤0.01%	1193

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Sandy Spring Bank's CPRX Position: Q1 2025 in Review

Sandy Spring Bank held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2025 at 2 shares worth $49. The position accounts for ﹤0.01% of the portfolio, ranked #1198.

Sandy Spring Bank first reported a position in CPRX in Q4 2024 and has held it in 2 quarters since. 371 funds tracked by Wall St. Rank hold CPRX as of Q1 2025.

Sandy Spring Bank held 2 shares of Catalyst Pharmaceutical worth $49 as of Q1 2025.
Sandy Spring Bank left its Catalyst Pharmaceutical share count unchanged in Q1 2025.
Catalyst Pharmaceutical made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #1198 holding.
Sandy Spring Bank first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 2 quarters since.
371 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.